GENE ONLINE|News &
Opinion
Blog

2021-08-22| ChinaSpecial

HebaBiz Biotech Obtains FDA Clearance to Trial Cancer Drug Against Aggressive Brain Tumor

by Rajaneesh K. Gopinath
Share To
Glioblastoma (GBM) is the most common and aggressive form of brain tumor with a poor prognosis. Existing treatment includes surgery, followed by radiotherapy, and chemotherapy. Yet, several patients develop resistance to treatments, suffer from relapse, and die, creating a significant unmet need in this area.

At this juncture, Beijing-based HebaBiz Biotech announces that the FDA has accepted IND for its innovative anti-cancer drug for Glioblastoma trials in the US.

GO Prime with only $1.49 now

LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top